BTMD
biote Corp.2.6700
+0.0500+1.91%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
127.76MP/E (TTM)
3.38Basic EPS (TTM)
0.79Dividend Yield
0%Recent Filings
10-K
FY2025 results
biote Corp. posted FY2025 revenue of $192.2M, down 2.5% y/y from $197.2M, with net income vaulting to $31.6M from near-breakeven. Procedure revenue dropped 8.8% y/y amid slower clinic adds and softer volumes from existing practitioners, yet dietary supplements surged, offsetting some pain. Q4 momentum faltered on recall-related inventory hits, but vertical integration via Asteria Health trimmed pellet costs 19%. Cash from operations held at $35M; debt steady with $45M revolver headroom. No annual guidance disclosed. Geographic concentration risks quarterly flows.
8-K
Q4 revenue dips, profit surges
Biote reported Q4 2025 revenue of $46.4 million, down 6.9% from prior year due to 13.0% procedure revenue drop, offset by 16.0% dietary supplements growth; full-year revenue fell 2.5% to $192.2 million yet net income soared to $31.6 million. Sales reorganization cut expenses, boosting operating income 12.5%. Guides 2026 revenue above $190 million, procedure growth resuming H2.
8-K
Voluntary hormone pellet recall
biote's Asteria Health subsidiary voluntarily recalled hormone pellet lots shipped May 20, 2025–January 19, 2026, due to potential metal particulates, with FDA knowledge. Expect $1.3M Q4 inventory write-off and ~$1.0M additional 2026 costs. Supply to practitioners unaffected. Risks could alter estimates.
10-Q
Q3 FY2025 results
biote's Q3 revenue dipped 6.7% y/y to $48.0M, with product sales down to $47.0M from $49.8M, yet gross margin expanded as pellet costs fell 11.4% amid Asteria Health integration. Operating income held at $8.3M despite SG&A up 9.3% from marketing shifts; diluted EPS landed at $0.22 on 36.7M shares. OCF through 9M slowed to $27.6M, FCF not disclosed in the 10-Q; cash sits at $28.0M with $50M revolver available and $104.7M term debt (7.01%, due 2027). Share repurchases trimmed 1.0M Class A shares. Ongoing litigation shadows founder settlements.
8-K
Biote Q3 revenue dips 6.7%
Biote Corp. reported Q3 2025 revenue of $48.0 million, down 6.7% year-over-year, with procedure revenue dropping 10.4% amid commercial team restructuring, yet gross margin rose to 71.8% from manufacturing efficiencies. Net income fell to $9.2 million from $12.7 million, while Adjusted EBITDA declined 20.5% to $12.9 million. The company repurchased one million shares and amended settlements to repurchase founder shares for $12.5 million and $18.5 million, saving costs. Biote reiterates 2025 guidance of revenue above $190 million and Adjusted EBITDA above $50 million. Commercial shifts challenge short-term growth.
AIBT
Aibotics Inc.
0.00+0.00
AIRS
AirSculpt Technologies, Inc.
2.57-0.06
BDMD
Baird Medical Investment Holdin
1.37+0.02
BICX
BioCorRx Inc.
0.34-0.04
BSEM
BioStem Technologies, Inc.
3.84-0.11
BTCY
Biotricity Inc.
0.38+0.04
CPMD
Cannapharmarx Inc.
0.00-0.00
IBO
Impact BioMedical, Inc.
0.44-0.02
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NUTX
Nutex Health Inc.
171.72-4.06